Why Inovio Pharmaceuticals, Inc.’s (INO) Stock Is Up 5.73%
As of Tuesday, September 22, Inovio Pharmaceuticals, Inc.’s INO share price has surged by 5.73%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: Inovio Pharmaceuticals, Inc. (INO)
Inovio Pharmaceuticals, Inc. INO
$1.20
-0.06
-4.40%
September 24, 2026 1:31:15 PM
EST
Volume: 1,341,130
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company’s partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Commentary & Analysis
Why Inovio Pharmaceuticals, Inc.’s (INO) Stock Is Up 6.52%
As of Thursday, September 17, Inovio Pharmaceuticals, Inc.’s INO share price has surged by 6.52%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Inovio Pharmaceuticals, Inc.’s (INO) Stock Is Up 5.33%
As of Wednesday, September 02, Inovio Pharmaceuticals, Inc.’s INO share price has surged by 5.33%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Inovio Pharmaceuticals, Inc.’s (INO) Stock Is Up 7.44%
As of Friday, August 21, Inovio Pharmaceuticals, Inc.’s INO share price has surged by 7.44%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Inovio Pharmaceuticals, Inc.’s (INO) Stock Is Up 17.76%
As of Friday, August 14, Inovio Pharmaceuticals, Inc.’s INO share price has surged by 17.76%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | INO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $129.2 | $259.1 | 23% |
|
| Shares Out (Mil) | 81.6 | 54.3 | 58% |
|
| Institutional Ownership | 98.8% | 92.8% | 82% |
|
| Float (Mil) | 95.8 | 42.0 | 60% |
|
| Beta | 1.51 | 0.95 | 83% |
|
| Avg Daily Volume (000s) | 2,796 | 637 | 85% |
|
| Price Change (52-week) |
(49.8%) | 52.5% | 17% |
|
| Growth | INO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | 12.6% | (10.1%) | 59% |
|
| EPS (5yr) | 32.4% | 15.8% | 83 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.2%) | (15.6%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 2 | |
| Current EPS | ($0.195) | ($0.730) | ($0.440) | |
| Month Ago EPS | ($0.195) | ($0.730) | ($0.440) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.247) | ($1.140) | ($0.410) | |
| Year/Year Chg | 163.5% | (59.7%) | (93.9%) | |
| Financials | INO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($67) | ($43) | 14% |
|
| EPS (TTM) | ($1.034) | ($1.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($81) | ($32) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $7 | $2 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | $93 | $175 | 20% |
|
| Valuation | INO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 25.00 | 2.54 | 97% |
|
| P/E | na | 18.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | INO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (114.6%) | (47.5%) | 5% |
|
| ROE | (409.9%) | (54.9%) | 2% |
|
| Liabilities to Assets | 91.1% | 29.4% | 88% |
|
| F-Score | 0 | 3 | 0% |
|
Inovio Pharmaceuticals, Inc. did not pass any screens on 9/23/2026.
